OPT-80, a macrocyclic antimicrobial agent for the treatment of clostridium difficile infections: A review

Expert Opinion on Investigational Drugs

Volumn 17, Issue 4, 2008, Pages 547-553

  Gerber, Michael ^a   Ackermann, Grit ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Antimicrobial therapy; Clostridium difficile; OPT 80

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BACITRACIN; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; FUSIDIC ACID; LINEZOLID; METRONIDAZOLE; NITAZOXANIDE; OP 1118; PLACEBO; RAMOPLANIN; RIFAMPICIN; TEICOPLANIN; TELITHROMYCIN; TIACUMICIN B; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOSIDE;

ABSENCE OF SIDE EFFECTS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; GENOTOXICITY; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTIOUS DIARRHEA; LD 50; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; ANIMAL; CHEMICAL STRUCTURE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PSEUDOMEMBRANOUS COLITIS;

ANIMALS; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GLYCOSIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; TREATMENT OUTCOME;

EID: 42149188777     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.4.547     Document Type: Review

References (47)

1. Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994;18(Suppl 4):S265-72
2. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-53
3. Ackermann G, Thomalla S, Ackermann F, et al. Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea. J Med Microbiol 2005;54:149-53
4. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9
5. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41
6. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(Suppl 6):2-18
7. Zaiss NH, Weile J, Ackermann G, et al. A case of Clostridium difficile-associated disease due to the highly virulent clone of Clostridium difficile PCR ribotype 027, March 2007 in Germany. Euro Surveill 2007;12:E071115.1
8. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006;145:758-64
9. Larson HE, Borriello SP. Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters. Antimicrob Agents Chemother 1990;34:1348-53
10. Brazier JS, Fawley W, Freeman J, Wilcox MH. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001;48:741-2
11. Jang SS, Hansen LM, Breher JE, et al. Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. Clin Infect Dis 1997;25(Suppl 2):S266-7
12. Pelaez T, Alcala L, Alonso R, et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005;49:1157-9
13. Wong SS, Woo PC, Luk WK, Yuen KY. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999;34:1-6
14. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586-90
15. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7
16. Rafferty ME, McCormick MI, Bopp LH, et al. Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect Control Hosp Epidemiol 1997;18:342-4
17. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7
18. Louie T, Emery W, Krulicki W, et al. Quantitative C. difficile and anaerobic flora cultures during treatment of C. difficile-associated diarrhea with PAR-101 (OPT-80) [abstract P-1649]. 16th ECCMID, Nice, France; 2006
19. Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48:2280-2
20. Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48:4898-902
21. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-9
22. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004;48:4430-4
23. Louie T, Emery W, Krulicki W, et al. PAR-101 is selectively effective against Clostridium difficile in-vivo and has minimal effect on the anaerobic fecal flora [abstract LB2-30]. 45th ICAAC, Washington, DC, USA; 2005
24. Swanson RN, Hardy DJ, Shipkowitz NL, et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 1991;35:1108-11
25. Shangle S, Lee C, Okumu F, et al. Safety and pharmacokinetics of OPT-80 in human volunteers [abstract A-5]. 44th ICAAC, Washingthn, DC, USA; 2004
26. Okumu F, Walsh RB, Sears P, Shue Y-K. Safety and pharmacokinetics of OPT-80, a novel antibiotics for treatment of Clostridium difficile associated diarrhea (CDAD) [abstract F-726]. 44th ICAAC, Washington, DC. USA; 2004
27. Louie T, Miller M, Donskex C, et al. Safety, pharmacokinetics and outcomes of PAR-101 in healthy subjects and patients with Clostridium difficile-associated diarrhea (CDAD) [abstract LB2-29]. 45th ICAAC, Washington, DC, USA; 2005
28. Parenti F, Pagani H, Beretta G. Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies. J Antibiot (Tokyo) 1975;28:247-52
29. Coronelli C, White RJ, Lancini GC, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization. J Antibiot (Tokyo) 1975;28:253-9
30. Theriault RJ, Karwowski JP, Jackson M, et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J Antibiot (Tokyo) 1987;40:567-74
31. Hochlowski JE, Swanson SJ, Ranfranz LM, et al. Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination. J Antibiot (Tokyo) 1987;40:575-88
32. Johnson AP. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Investig Drugs 2007;8:168-73
33. Par Pharmaceutical Announces Equity Investment in Optimer Pharmaceuticals, May 3, 2005. Available from: http://www.parpharm.com/ media/NR_20050503.jsp [Last accessed 22 February 2008]
34. Par Pharmaceutical Returns Par-101 Marketing Rights to Optimer Pharmaceuticals, Feb. 27, 2007. Available from: http://www.parpharm.com/ media/NR_20070227.jsp [Last accessed 22 February 2008]
35. Gualtieri M, Villain-Guillot P, Latouche J, et al. Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin. Antimicrob Agents Chemother 2006;50:401-2
36. Osburne MS, Sonenshein AL. Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis. J Virol 1980;33:945-53
37. Babakhani F, Seddon J, Robert N, et al. Effect of inoculum, pH, and cations on the in vitro activity of OPT-80 vs. Clostridium difficile [abstract D-1648]. 45th ICAAC, Washington, DC, USA; 2005
38. Babakhani F, Seddon J, Robert N, et al. Narrow spectrum activity and low fecal protein binding of OPT-80 and its major hydrolysis metabolite (OP-1118) [abstract E-2076]. 47th ICAAC, Chicago, IL, USA, 2007
39. Babakhani F, Robert N, Shangle S, et al. Antimicrobial activity and post-antibiotic effect (PAE) of OPT-80 a new makrocyclic compound, against Clostridium difficile [abstract E-2048]. 44th ICAAC, Washington, DC, USA; 2004
40. Babakhani F, Shangle S, Robert N, et al. Resistance development, cross-resistance, and synergy studies of OPT-80 [abstract E-2047]. 44th ICAAC, Washington, DC, USA; 2004
41. Optimer Pharmaceuticals initiates second Phase 3 trial of OPT-80 for CDAD, Jan 1, 2007. Available from: http://www.optimerpharma.com/ news.asp?news_story=23&page_num=4 [Last accessed 22 February 2008]
42. Citron DM, Merriam CV, Tyrrell KL, et al. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003;47:2334-8
43. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004;54:211-6
44. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 2003;47:337-41
45. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-7
46. Ackermann G, Adler D, Rodloff AC. In vitro activity of linezolid against Clostridium difficile. J Antimicrob Chemother 2003;51:743-5
47. Karlowski JP, Laing NM, Alfa M, et al. In vitro antimicrobial activities of OPT-80, rifaximin, tigecycline, and comparators against toxin-positive Clostridium difficile cultured from diarrheal stool specimens [abstract E-2080]. 47th ICAAC, Chicago, IL, USA; 2007